The DME Deal Isn’t Won at Close: Why Integration is One of the Biggest Variables in M&A Returns

Closing an acquisition creates the opportunity for value, but successful integration determines how much of that value is preserved and realized.

For DME organizations and investors, integration extends beyond systems and processes. Maintaining revenue, protecting referral relationships, ensuring patient continuity, and preparing employees for operational transitions are critical to achieving the investment thesis.

In this perspective, CWH Advisors explores why integration is one of the most important variables in DME M&A returns, the operational risks that can erode acquired value, and how thoughtful planning, execution, and performance measurement can help protect and strengthen enterprise value.

Please complete the form to receive this white paper. Upon submission, the white paper will

Revenue Cycle Management: The Untapped Value Creation Lever in DME

Revenue cycle management (RCM) is more than a billing function. For durable medical equipment (DME) providers, it plays a critical role in cash flow, earnings quality, growth capacity, and enterprise value. Yet even mature organizations can experience significant revenue leakage due to payer complexity, fragmented workflows, and gaps in operational accountability. Drawing on recent revenue […]

Medically Integrated Pharmacy: The Next Frontier of Value-Based Specialty and Infusion Care

Medically integrated pharmacy (MIP) is moving beyond its roots in oncology and emerging as a significant growth opportunity across specialty care. By embedding pharmacy services directly within physician practices and health systems, the model brings prescribing, dispensing, financial counseling, adherence monitoring, and clinical management together at the point of care—while creating new, durable revenue streams. […]

Ambulatory Infusion Options and the Regulatory Road Ahead: Why Federal and State Legislation Will Determine the Next Decade of Value in Home and Ambulatory Infusion

Home and ambulatory infusion are entering a period of significant regulatory change as federal and state policies reshape where care is delivered, how providers are reimbursed, and which operating models are positioned to create value. In this perspective, we examine the legislative and regulatory developments shaping the sector, from Medicare home infusion coverage and site-neutral […]

Modeling the Next Specialty Therapy Line: Predictive Financial Modeling for Neurology, Rare Disease and Cardiology Expansion in Home Infusion

Home infusion providers are entering a new phase of growth, but not all specialty therapy lines offer the same strategic opportunity. As legacy infusion categories mature and reimbursement pressures increase, providers and investors are looking to higher-growth specialties that can drive long-term value creation. In this perspective, we examine the financial and operational potential of […]

The DME Deal Isn’t Won at Close: Why Integration is One of the Biggest Variables in M&A Returns

You might also like

Revenue Cycle Management: The Untapped Value Creation Lever in DME

Medically Integrated Pharmacy: The Next Frontier of Value-Based Specialty and Infusion Care

Ambulatory Infusion Options and the Regulatory Road Ahead: Why Federal and State Legislation Will Determine the Next Decade of Value in Home and Ambulatory Infusion

Modeling the Next Specialty Therapy Line: Predictive Financial Modeling for Neurology, Rare Disease and Cardiology Expansion in Home Infusion

Providing guidance to healthcare organizations at inflection points.